197 related articles for article (PubMed ID: 36477676)
1. Genetic landscape of chronic myeloid leukemia.
Ochi Y
Int J Hematol; 2023 Jan; 117(1):30-36. PubMed ID: 36477676
[TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
3. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of clonal evolution in chronic myeloid leukemia].
Ochi Y
Rinsho Ketsueki; 2023; 64(5):369-375. PubMed ID: 37271527
[TBL] [Abstract][Full Text] [Related]
6. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
7. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Patel AB; O'Hare T; Deininger MW
Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
[TBL] [Abstract][Full Text] [Related]
8. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
10. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
12. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
13. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
14. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
15. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
[TBL] [Abstract][Full Text] [Related]
16. Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S; Fernandes A; Shahrin N; Maqsood M; Shanmuganathan N; Wadham C
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394774
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
18. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
19. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Adnan-Awad S; Kankainen M; Mustjoki S
Leuk Lymphoma; 2021 Sep; 62(9):2064-2078. PubMed ID: 33944660
[TBL] [Abstract][Full Text] [Related]
20. [Next treatment for TKI-resistant CML].
Takahashi N
Rinsho Ketsueki; 2023; 64(9):981-987. PubMed ID: 37793874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
